Galecto, Inc.

📍 Copenhagen, Denmark🗓 Founded 2011👥 59 employees💰 Last funded Jun 2018
Biotechnology Research🌐 galecto.com
Website LinkedIn
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2011
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in Galecto, Inc.?
Galecto, Inc. has 1 investors on record on gritt.io and 1 late-stage investors.
When did Galecto, Inc. last raise funding?
The most recent investment in Galecto, Inc. recorded on gritt.io was in June 2018.
When was Galecto, Inc. founded?
Galecto, Inc. was founded in 2011.
What industry is Galecto, Inc. in?
Galecto, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Galecto, Inc. based?
Galecto, Inc. is headquartered in Copenhagen, Denmark.